Colorectal Cancer | NCIC CO.17
A phase III randomised study of cetuximab (ERBITUX™, C225) and best supportive care versus best supportive care in patients with pre-treated metastatic epidermal growth factor receptor (EGFR) positive colorectal carcinoma.
Schema
* Prior to submission to the reference laboratory of representative slides of the diagnostic tumour tissue for EGFR testing.
Summary
Therapeutic options for patients with metastatic colorectal cancer whose cancers have progressed after treatment with standard therapies are limited. Cetuximab therapy is a new treatment targeting the epidermal growth factor receptor (EGFR, a protein on the surface of many cancer cells). Cetuximab can attach to this protein and may stop cancer growth. This study will examine the effect of cetuximab on length and quality of life in people with advanced EGFR positive colorectal cancer whose cancer has progressed after chemotherapy.
